J Korean Ophthalmol Soc.  2003 Jun;44(6):1392-1396.

The Inhibitory Effect of Ticlopidine on VEGF Induced Corneal Neovascularization

• Park YK
• Kim MY
• Bae SR

Abstract

PURPOSE
Ticlopidine, which has platelet inhibitory property, is currently used in peripheral arterial obstructive disease, ischemic stroke, and coronary artery disease. It is also known to have antiangiogenesis effect. We studied the effect of ticlopidine on rabbit corneal angiogenesis induced by VEGF. METHODS: In control group, a hydron pellet containing 300ng VEGF and phosphate buffered saline(PBS) was implanted intrastromally in the superior cornea. In treatment group, a hydron pellet containing 300ng VEGF and 375micro gram ticlopidine was implanted as the same manner. At 3, 5, and 7 day after implantation, we examined corneas under the microscope and estimated the angiogenesis score. RESULTS: At 5 and 7 day after implantation, ticlopidine-treated group had mean angiogenesis score of 27.9 and 49.1(p=0.014, independent t-test), while control group scored 13.0 and 25.3(p=0.004). CONCLUSIONS: In a rabbit corneal pocket assay, ticlopidine appears to have inhibitory effect on VEGF-induced corneal angiogenesis.

Keyword

Angiogenesis; Neovascularization; Ticlopidine; VEGF

MeSH Terms

Angiogenesis Inhibitors
Arterial Occlusive Diseases
Blood Platelets
Cornea
Corneal Neovascularization*
Coronary Artery Disease
Stroke
Ticlopidine*
Vascular Endothelial Growth Factor A*
Angiogenesis Inhibitors
Ticlopidine
Vascular Endothelial Growth Factor A